Established 2016|Australia's longest-standing research supplier|Trusted by 4,000+ researchers & labs|Batch-tested · Fast AU-wide dispatch
VCP Australia
Sign In
Peptides — Growth Hormone Axis

Ipamorelin

A synthetic pentapeptide growth-hormone secretagogue described in early animal pharmacology as a selective GH-releaser with minimal effect on cortisol or prolactin.

Education Hub

Pre-clinical mechanism

Acts as an agonist at the ghrelin / growth hormone secretagogue receptor (GHS-R1a) in the pituitary, eliciting GH release without the broader pituitary effects seen with some earlier GHRPs in pre-clinical work.

Key pre-clinical findings

  • Original pig and rat pharmacology: dose-dependent GH release without elevation of ACTH, cortisol or prolactin (Raun et al., 1998).

Primary literature

Ipamorelin, the first selective growth hormone secretagogue

Raun K, Hansen BS, Johansen NL, et al. · European Journal of Endocrinology · 1998

Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.

Research-Use Notice

Products displayed on this website may be intended for laboratory, analytical or research purposes only where applicable. They are not intended to diagnose, treat, cure or prevent any disease. They are not supplied for human or animal consumption unless expressly stated and lawfully permitted. Customers are responsible for understanding and complying with all applicable laws and regulations. Product information is provided for informational purposes only and does not constitute medical advice.

Read Full Disclaimer